Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]
Viruses, 2020 Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
John Foerster, Aleksandra Molęda
doaj +4 more sources
Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid [PDF]
Annals of Medicine, 2023 Aim: Bullous pemphigoid (BP) is an organ-specific autoimmune bullous disease characterized by autoantibodies that target the cellular adhesion molecules BP180 and BP230.
Fangyuan Chen +4 more
doaj +2 more sources
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis [PDF]
Pharmaceutics, 2023 Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj +2 more sources
Interleukin 13 Promotes Maturation and Proliferation in Metaplastic GastroidsSummary [PDF]
Cellular and Molecular Gastroenterology and HepatologyBackground & Aims: Type 2 innate lymphoid cells (ILC2s) and interleukin-13 (IL-13) promote the onset of spasmolytic polypeptide-expressing metaplasia (SPEM) cells. However, little is known about molecular effects of IL-13 in SPEM cells. We now sought
Ela W. Contreras-Panta +8 more
doaj +2 more sources
Cells, 2021 Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. SSc causes damage to the skin and various organs including the lungs, heart, and digestive tract, but the extent of the damage varies from patient to patient.
Yoshihito Shima
doaj +1 more source
Characterization of the Interaction between Interleukin-13 and Interleukin-13 Receptors [PDF]
Journal of Biological Chemistry, 2005 Interleukin-13 (IL-13) possesses two types of receptor: the heterodimer, composed of the IL-13Ralpha1 chain (IL-13Ralpha1) and the IL-4Ralpha chain (IL-4Ralpha), transducing the IL-13 signals; and the IL-13Ralpha2 chain (IL-13Ralpha2), acting as a nonsignaling "decoy" receptor.
Kazuhiko, Arima +8 more
openaire +2 more sources
Interleukin-13 (IL-13) Pathway [PDF]
Science's STKE, 2005 Interleukin-13 (IL-13), like IL-4, is a cytokine produced by T H 2 type helper T cells in response to signaling through the T cell antigen receptor and by mast cells and basophils upon cross-linkage of the high-affinity receptor for immunoglobulin E (IgE). It is also produced by activated eosinophils.
Ann, Kelly-Welch +2 more
openaire +2 more sources
Selective IL-13 inhibitors for the treatment of atopic dermatitis
Drugs in Context, 2021 Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves +2 more
doaj +1 more source
Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis
Frontiers in Immunology, 2023 BackgroundFibrostenotic disease is a common complication in Crohn’s disease (CD) patients hallmarked by transmural extracellular matrix (ECM) accumulation in the intestinal wall.
Kristina Koop +19 more
doaj +1 more source
Association of interleukin-13 gene variants with susceptibility to brucellosis [PDF]
Trends in Pharmaceutical Sciences, 2016 Brucella is an intracellular Gram-negative bacterium. Previous reports showed that gene polymorphisms of cytokines can affect resistance or susceptibility to Brucella infection.
Sayed-Jalal-Aladin Ashraf-Mansuri +5 more
doaj +2 more sources